Clinical trial · Observational
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
NCT05246345CI-TRIAL-00072844RAVENrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| CLL | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| Progressive Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | CURATED_BROADER | 0.78 |
| Refractory Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | CURATED_BROADER | 0.78 |
| Relapsed Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
- description
- Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
Primary outcomes (1)
- measure
- Frequency measurement of BCL2 gene mutations
- timeFrame
- immediately after the chronic lymphocytic leukemia progression
- description
- Frequency measurement of BCL2 gene mutations in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Secondary outcomes (5)
- measure
- Frequency measurement of 1q amplification
- timeFrame
- immediately after the chronic lymphocytic leukemia progression
- description
- Frequency measurement of 1q amplification in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than or equal to 18 years old; * chronic lymphocytic leukemia diagnosis according to iwCLL criteria; * refractory and/or relapsed disease during or after venetoclax treatment; * tumor samples available. * Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome. * Patients must be able to express their opposition to be enrolled in this study, if need be. * Patients must be affiliated at the French Social Security system Exclusion Criteria: Patients of their legal guardians refusing to participate \-
References
Publications (0)
Data not yet available
No reference posted for this study.